活発な乾癬性関節炎の成人参加者の治療のための標的療法の研究
能動的な乾癬性関節炎を伴う成人被験者の治療のための標的療法の第2相マルチセンター、無作為化、プラットフォーム研究
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:ABBVIE CALL CENTER
- 電話番号:844-663-3742
- メール:abbvieclinicaltrials@abbvie.com
研究場所
-
-
California
-
Huntington Beach、California、アメリカ、92648-5994
- 募集
- Newport Huntington Medical Group /ID# 272764
-
コンタクト:
- Site Coordinator
- 電話番号:714-923-7112
-
-
Florida
-
Avon Park、Florida、アメリカ、33825
- 募集
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
コンタクト:
- Site Coordinator
- 電話番号:863-314-8555
-
Clearwater、Florida、アメリカ、33765
- 募集
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando、Florida、アメリカ、32819
- 募集
- HMD Research LLC /ID# 273086
-
Tamarac、Florida、アメリカ、33321
- 募集
- West Broward Rheumatology Associates /ID# 272892
-
Tampa、Florida、アメリカ、33606
- 募集
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
コンタクト:
- Site Coordinator
- 電話番号:(813) 870-1292
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie、Illinois、アメリカ、60076
- 完了
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook、Illinois、アメリカ、60527
- 募集
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland、Maryland、アメリカ、21502
- 完了
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- 募集
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
コンタクト:
- Site Coordinator
- 電話番号:603-650-4717
-
-
Ohio
-
Middleburg Heights、Ohio、アメリカ、44130
- 募集
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville、Pennsylvania、アメリカ、16635
- 募集
- Altoona Center For Clinical Research /ID# 272593
-
コンタクト:
- Site Coordinator
- 電話番号:814-296-6108
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38119
- 募集
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin、Texas、アメリカ、78745
- 募集
- Tekton Research - West Gate /ID# 272765
-
Frisco、Texas、アメリカ、75035
- 募集
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston、Texas、アメリカ、77089-6142
- 募集
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio、Texas、アメリカ、78251
- 募集
- Tekton Research, LLC /ID# 272901
-
Tomball、Texas、アメリカ、77375
- 募集
- DM Clinical Research - Tomball /ID# 272760
-
-
-
-
Quebec
-
Sherbrooke、Quebec、カナダ、J1G 2E8
- 募集
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières、Quebec、カナダ、G9A 3X2
- 募集
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、カナダ、S7H 0P4
- 募集
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
-
Uherské Hradiště、チェコ、686 01
- 募集
- Medical Plus Research /ID# 272363
-
Zlín、チェコ、760 01
- 募集
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno、Brno-mesto、チェコ、638 00
- 募集
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín、Moravian-Silesian Region、チェコ、748 01
- 募集
- L.K.N. Arthrocentrum /ID# 272366
-
-
-
-
-
Budapest、ハンガリー、1027
- 募集
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest、ハンガリー、1023
- 募集
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc、Borsod-Abauj Zemplen county、ハンガリー、3529
- 募集
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár、Fejér、ハンガリー、8000
- 募集
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém、Fejér、ハンガリー、8200
- 募集
- Vital-Medicina /ID# 272855
-
-
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06001
- 募集
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire、Auvergne-Rhône-Alpes、フランス、69300
- 募集
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours、Indre-et-Loire、フランス、37170
- 募集
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans、Loiret、フランス、45067
- 完了
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux、New Aquitaine、フランス、33076
- 完了
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、ポーランド、85-068
- 募集
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków、Masovian Voivodeship、ポーランド、05-800
- 募集
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw、Masovian Voivodeship、ポーランド、02-665
- 募集
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-351
- 完了
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag、Warmian-Masurian Voivodeship、ポーランド、82-300
- 完了
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
実験的:Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
実験的:Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
実験的:Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
実験的:Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
実験的:Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
実験的:Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
実験的:Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
実験的:Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
時間枠:At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
時間枠:Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
時間枠:At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
時間枠:At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
時間枠:At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
時間枠:At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- M25-191
- 2024-519291-11 (Substudy 1) (その他の識別子:EU CT)
- 2026-525937-21 (Substudy 2) (その他の識別子:EU CT)
- 2026-527719-41 (Substudy 3) (その他の識別子:EU CT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共有時間枠
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共有アクセス基準
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。